Solvay expands development pact with Wyeth
Solvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialization partnership announced in April 2004 between Solvay and Wyeth resulted in an NDA for bifeprunox for the treatment of patients with schizophrenia. Meanwhile development continues on two other early-phase neuroscience projects, SLV313 and SLV314, which were part of that agreement.
- check out the release on the deal
Related Articles:
Solvay earns $25M as obesity drug advances. Report
Wyeth licenses Pharmacopeia's JAK3 program. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

